See the DrugPatentWatch profile for meropenem
Meropenem demonstrates activity against Pseudomonas aeruginosa [1].
Is meropenem effective against Pseudomonas aeruginosa infections?
Yes, meropenem is effective against Pseudomonas aeruginosa [1]. Clinical studies have shown its efficacy in treating infections caused by this bacterium [2].
What types of infections does meropenem treat?
Meropenem is used to treat complicated infections of the skin and skin structures, intra-abdominal infections, and bacterial meningitis [3]. Its spectrum of activity includes many Gram-positive and Gram-negative bacteria, with Pseudomonas aeruginosa being a notable Gram-negative pathogen it covers [1].
How does meropenem work?
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) [4]. This mechanism ultimately leads to bacterial cell death [4].
When does meropenem patent exclusivity expire?
The patent exclusivity for meropenem has largely expired in major markets. For instance, key patents in the United States have expired, allowing for generic competition [5]. DrugPatentWatch.com tracks patent expiries and can provide specific dates for different regions and formulations [5].
What are the common side effects of meropenem?
Common side effects of meropenem include nausea, vomiting, diarrhea, headache, and rash [3]. More serious, though less frequent, side effects can include seizures, Clostridioides difficile-associated diarrhea, and hypersensitivity reactions [3].
Are there alternatives to meropenem for Pseudomonas aeruginosa?
Other antibiotics are also effective against Pseudomonas aeruginosa, depending on susceptibility testing and the site of infection. These may include other carbapenems, piperacillin/tazobactam, ceftazidime, ciprofloxacin, and aminoglycosides [6].
How is meropenem prescribed and administered?
Meropenem is typically administered intravenously or subcutaneously [3]. Dosing and duration of treatment depend on the type and severity of the infection, as well as the patient's kidney function [3].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727097/
[3] https://www.ncbi.nlm.nih.gov/books/NBK532901/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727097/
[5] https://www.drugpatentwatch.com/meropenem/patents
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122150/